First-of-its-kind technology provides individualized, actionable insights on dose and interval for infliximab
Published: February 23, 2022
Prometheus Laboratories recently announced the launch of PredictrPK IFX, which uses a machine learning algorithm to combine patient weight, current dose and interval, measured serum IFX, measured antibodies-to-infliximab and albumin levels to predict optimal, individualized infliximab dosing. This new technology can help validate existing treatment plans or investigate alternative doses and intervals.
Read the full press release from Prometheus Laboratories here: https://www.prometheuslabs.com/about_predictrpk/
Crohn's & Colitis Foundation
The Crohn's & Colitis Foundation is a non-profit, volunteer-fueled organization dedicated to finding the cures for Crohn's disease and ulcerative colitis, and to improving the quality of life of children and adults affected by these diseases. It was founded in 1967 by Irwin M. and Suzanne Rosenthal, William D. and Shelby Modell, and Henry D. Janowitz, M.D.